



## Complete Summary

---

### GUIDELINE TITLE

Hypertension.

### BIBLIOGRAPHIC SOURCE(S)

Texas Tech University Managed Health Care Network Pharmacy & Therapeutics Committee. Hypertension. Conroe (TX): University of Texas Medical Branch Correctional Managed Care; 2003 Apr. 9 p. [3 references]

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Texas Tech University Managed Health Care Network Pharmacy & Therapeutics Committee. Hypertension. Conroe (TX): Texas Department of Criminal Justice, University of Texas Medical Branch; 2001 Apr. 6 p.

## COMPLETE SUMMARY CONTENT

SCOPE  
METHODOLOGY - including Rating Scheme and Cost Analysis  
RECOMMENDATIONS  
EVIDENCE SUPPORTING THE RECOMMENDATIONS  
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
CONTRAINDICATIONS  
QUALIFYING STATEMENTS  
IMPLEMENTATION OF THE GUIDELINE  
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES  
IDENTIFYING INFORMATION AND AVAILABILITY  
DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

Hypertension

### GUIDELINE CATEGORY

Diagnosis  
Evaluation  
Management

Risk Assessment  
Treatment

## **CLINICAL SPECIALTY**

Family Practice  
Internal Medicine

## **INTENDED USERS**

Health Care Providers  
Pharmacists  
Physicians

## **GUIDELINE OBJECTIVE(S)**

To present guidelines on the detection, evaluation, and management of hypertension in incarcerated offenders within the Texas Department of Criminal Justice

## **TARGET POPULATION**

Incarcerated offenders within the Texas Department of Criminal Justice with hypertension or at risk for hypertension

## **INTERVENTIONS AND PRACTICES CONSIDERED**

### **Screening and Assessment**

1. Medical history, including risk factor stratification and detection of comorbidities
2. Physical examination and blood pressure reading
3. Laboratory tests to evaluate for target organ disease and comorbidities
  - Urinalysis
  - Complete blood count
  - Chemistry panel
  - Fasting lipid profile (cardiac risk)
4. Electrocardiogram (EKG)

### **Treatment**

1. Pharmacologic treatment
  - Diuretics (Furosemide, Hydrochlorothiazide, Metolazone, Triamterene)
  - Beta blockers (Atenolol, Metoprolol, Propranolol)
  - Calcium channel blockers (Amlodipine, Diltiazem, Verapamil)
  - Alpha-1 blockers (Doxazosin)
  - Alpha-2 agonists (Clonidine)
  - Angiotensin-converting enzyme (ACE) inhibitors (Enalapril)
  - Other agents (Minoxidil)
2. Education in lifestyle modification (e.g., weight management, exercise, specified diet modifications, smoking cessation, limitation of alcohol intake)

3. Ongoing monitoring of blood pressure and follow-up
4. Specialist referral, pharmacotherapy consult, or stabilization in infirmary setting, if indicated

## **MAJOR OUTCOMES CONSIDERED**

Not stated

## **METHODOLOGY**

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Searches of Electronic Databases

### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

Not stated

### **NUMBER OF SOURCE DOCUMENTS**

Not stated

### **METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Not stated

### **RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE**

Not applicable

### **METHODS USED TO ANALYZE THE EVIDENCE**

Review

### **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Not stated

### **METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Not stated

### **RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

Not applicable

### **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

## METHOD OF GUIDELINE VALIDATION

Not stated

## DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not applicable

## RECOMMENDATIONS

### MAJOR RECOMMENDATIONS

Many of the major recommendations are presented in an algorithm:

- [Hypertension](#)

#### Risk Stratification and Treatment\*

- **Risk Group A (No risk factors; No TOD/CCD\*\*)**

Blood Pressure High-Normal (130-139/85-89) -- Lifestyle modifications

Blood Pressure Stage 1 (140-159/90-99) -- Lifestyle modification (up to 12 mos.)

Blood Pressure Stage 2 & 3 (>160/>100) -- Drug therapy

- **Risk Group B (At least 1 risk factor, not including diabetes; No TOD/CCD)**

Blood Pressure High-Normal (130-139/85-89) -- Lifestyle modifications

Blood Pressure Stage 1 (140-159/90-99) -- Lifestyle modification (up to 6 mos.)\*\*\*

Blood Pressure Stage 2 & 3 (>160/>100) -- Drug therapy

- **Risk Group C (TOD/CCD and/or diabetes, with or without other risk factors)**

Blood Pressure High-Normal (130-139/85-89) -- Drug therapy\*\*\*\*

Blood Pressure Stage 1 (140-159/90-99) -- Drug therapy

Blood Pressure Stage 2 & 3 (>160/>100) -- Drug therapy

\*Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy.

\*\*TOD/CCD indicates target organ disease/clinical cardiovascular disease.

\*\*\*For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.

\*\*\*\*For those with heart failure, renal insufficiency, or diabetes.

## **Comorbidity Factors**

Patient Comorbidity or Demographics Which Represent Indications for Drug Therapy Modification

- Isolated systolic hypertension -- Start with diuretic (hydrochlorothiazide [HCTZ] 25 mg daily [QD]).
- Angina pectoris -- Start with beta blocker (Atenolol, Metoprolol), then calcium channel antagonist (CCA) (Verapamil, Diltiazem).
- Congestive heart failure (CHF) or ejection fraction <40% -- Start with angiotensin-converting enzyme (ACE) inhibitor (should be used even if on diuretic already).
- Diabetes mellitus -- Start with ACE inhibitor (Enalapril). Maintain blood pressure (BP) <130/80.
- Renal insufficiency -- (Serum creatinine [Scr] >2.5 mg/dL) -- Start with a loop diuretic (furosemide), beta-blocker or CCA (Verapamil and Diltiazem preferred); ACE inhibitor use is a relative contraindication in ACE inhibitor naive patient. Maintain blood pressure <130/85.
- Post myocardial infarction -- Start with non-intrinsic sympathomimetic activity (non-ISA) beta blocker (Metoprolol).
- Peripheral vascular disease -- Start with CCA (Verapamil, Diltiazem)
- Benign prostatic hypertrophy -- Start with alpha blocker (Doxazosin)
- Dyslipidemia -- Alpha agonist (Clonidine), alpha blocker (Doxazosin), ACE inhibitor or CCA
- Vascular headaches -- Start with beta-blocker (Atenolol, Metoprolol) or CCA (Verapamil, Diltiazem).
- Asthma or chronic obstructive pulmonary disease (COPD) -- Start with diuretic; beta-blocker is relative contraindication.
- Hyperuricemia or gout -- Start with beta-blocker; diuretic is relative contraindication.

## **Hypertension Disease Management Guidelines**

### **Detection and Confirmation**

The following procedures are recommended for the detection and confirmation of hypertension:

- Patients should be seated in a chair with their backs supported and their arms bared and supported at heart level. Patients should have refrained from smoking or ingesting caffeine during the 30 minutes prior to the reading.

- Blood pressure (BP) measurement should begin after the patient has been at rest for at least 5 minutes.
- Appropriate cuff size must be used to ensure accurate readings. The bladder within the cuff should encircle at least 80% of the arm. A large adult cuff should be kept in all clinics.
- Measurement of blood pressure with a mercury sphygmomanometer is the preferred method. However, a recently calibrated aneroid manometer or a validated electronic device can be used.
- Systolic blood pressure (SBP) and diastolic blood pressure (DBP) should be recorded.
- Two or more readings separated by 2 minutes should be obtained and averaged for proper confirmation. If these two readings differ by more than 5 mm Hg, additional readings should be obtained two weeks apart.

### **The Following Recommendations for Follow-up are Based on Initial Blood Pressure Readings**

Initial blood pressure (mm Hg)\* and Recommended Follow-up Schedule\*\*

- Systolic <130; Diastolic <85 -- Recheck in two years
- Systolic 130-139; Diastolic 85-89 -- Recheck in 1 year\*\*
- Systolic 140-159; Diastolic 90-99 -- Confirm within 2 months\*\*
- Systolic 160-179; Diastolic 100-109 -- Evaluate or refer to source of care within 1 month
- Systolic  $\geq$ 180; Diastolic  $\geq$ 110 -- Evaluate or refer to source of care immediately or within 1 week depending upon clinical situation

\*If systolic and diastolic categories are different, follow up should be for the shorter time (e.g. 160/86 mm Hg should be evaluated or referred within one month).

\*\*Modify the scheduling for follow up according to reliable information about past blood pressure measurements, other cardiovascular risk factors, or target organ disease.

\*\*\*Provide advice about lifestyle modifications.

### **Medical History**

- Known duration and levels of elevated blood pressure
- Patient history or symptoms of coronary heart disease (CHD), heart failure, cerebrovascular disease, peripheral vascular disease, renal disease, diabetes mellitus, dyslipidemia, gout, or sexual dysfunction
- Family history of high blood pressure, premature coronary heart disease, stroke, diabetes, dyslipidemia, or renal disease
- Symptoms suggestive of hypertension (headache, nose bleeds, dizziness, abnormal physical exam)
- History of recent changes in weight, leisure time physical activity, and smoking or tobacco use
- Dietary assessment including intake of sodium, alcohol, saturated fat, and caffeine

- History of all prescribed and over-the-counter (OTC) medication, herbal remedies, and illicit drugs
- Results and adverse effects of past antihypertensive therapy
- Psychosocial and environmental factors that may influence hypertensive control

### **Physical Exam**

- Two or more blood pressure readings separated by 2 minutes with the patient supine or seated
- Verification in the contralateral arm (if values are different, the higher value should be used)
- Measurement of weight, height, and waist circumference
- Fundoscopic examination for hypertensive retinopathy (i.e., arteriolar narrowing, focal arteriolar constrictions, arteriovenous crossing changes, hemorrhages and exudates, disc edema)
- Examination of the neck for carotid bruits, distended veins, or enlarged thyroid gland
- Examinations of the heart for abnormalities in the rate and rhythm, increased size, precordial heave, clicks, murmurs, and third and fourth heart sounds
- Examination of the lungs for rales and evidence for bronchospasm
- Examination of the abdomen for bruits, enlarged kidney, masses, and abnormal aortic pulsation
- Examination of the extremities for diminished or absent peripheral arterial pulsations, bruits, and edema
- Neurological assessment

### **Routine Laboratory Test**

Routine laboratory test recommended prior to initiating therapy and annually to determine end organ damage and other risk factors include:

- Urinalysis (UA)
- Complete blood count (CBC)
- Chemistry panel (e.g., Chem 20)
- Fasting lipid profile (cardiac risk panel)
- Electrocardiogram (EKG)

### **Secondary Causes of Hypertension**

- Renal disease
- Coarctation of the aorta
- Primary aldosteronism
- Cushing's syndrome
- Pheochromocytoma
- Pregnancy
- Drug-induced

### **Life Style Modification**

- Lose weight if over weight

- Increase aerobic activity (30-45 minutes most days of the week)
- Reduce sodium intake
- Maintain adequate intake of dietary potassium
- Maintain adequate intake of dietary calcium and magnesium for general health
- Stop smoking and reduce intake of dietary saturated fat and cholesterol for overall cardiovascular health
- Limit alcohol intake

## CLINICAL ALGORITHM(S)

An algorithm is provided for: [Hypertension](#).

## EVIDENCE SUPPORTING THE RECOMMENDATIONS

### TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

This guideline was adapted from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI express). NIH publication No. 03-5233, May 2003.

## BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

### POTENTIAL BENEFITS

Improved detection and appropriate evaluation and management of hypertension in incarcerated offenders within the Texas Department of Criminal Justice

### POTENTIAL HARMS

Not stated

## CONTRAINDICATIONS

### CONTRAINDICATIONS

- *Angiotensin-converting enzyme (ACE) Inhibitor*. Relative contraindication in ACE inhibitor naïve patients with renal insufficiency.
- *Beta-blocker*: Relative contraindication in patients with asthma or chronic obstructive pulmonary disease (COPD)
- *Diuretic*: Relative contraindication in patients with hyperuricemia or gout.

## QUALIFYING STATEMENTS

### QUALIFYING STATEMENTS

The pathways do not replace sound clinical judgment nor are they intended to strictly apply to all patients.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

### IMPLEMENTATION TOOLS

Clinical Algorithm

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Living with Illness

### IOM DOMAIN

Effectiveness  
Patient-centeredness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Texas Tech University Managed Health Care Network Pharmacy & Therapeutics Committee. Hypertension. Conroe (TX): University of Texas Medical Branch Correctional Managed Care; 2003 Apr. 9 p. [3 references]

### ADAPTATION

This guideline was adapted from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI express). NIH publication No. 03-5233, May 2003.

### DATE RELEASED

1997 Mar (revised 2003 Apr)

### GUIDELINE DEVELOPER(S)

University of Texas Medical Branch Correctional Managed Care - Academic Institution

**SOURCE(S) OF FUNDING**

University of Texas Medical Branch Correctional Managed Care

**GUIDELINE COMMITTEE**

Clinical Guidelines Committee on Hypertension

**COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

*Committee Members:* Owen Murray, DO; Edward Coffey, RPh; Renee Lenz, PharmD

**FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST**

Not stated

**GUIDELINE STATUS**

This is the current release of the guideline.

This guideline updates a previous version: Texas Tech University Managed Health Care Network Pharmacy & Therapeutics Committee. Hypertension. Conroe (TX): Texas Department of Criminal Justice, University of Texas Medical Branch; 2001 Apr. 6 p.

**GUIDELINE AVAILABILITY**

Print copies: Available from University of Texas Medical Branch (UTMB), 3009A HWY 30 West, Huntsville, TX, 77340.

**AVAILABILITY OF COMPANION DOCUMENTS**

None available

**PATIENT RESOURCES**

None available

**NGC STATUS**

This NGC summary was completed by ECRI on March 12, 2003. The information was verified by the guideline developer on March 24, 2003. This summary was updated by ECRI on April 21, 2004.

**COPYRIGHT STATEMENT**

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

## DISCLAIMER

### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 10/6/2008

